Lisberg et al. reported a phase II trial of pembrolizumab in TKI-naive patients with advanced EGFR-mutated, PD-L1-positive NSCLC and concluded that pembrolizumab is not appropriate as a first-line treatment for EGFR-mutated NSCLC before EGFR-TKI therapy (Lisberg et al. 2018). Here, EGFR is linked to non-small cell lung carcinoma.